Tomohiko Ohta

List of Publications by Year
in descending order

69 papers	5,122 citations	109137 35 h-index	95083 68 g-index
71 all docs	71 docs citations	71 times ranked	6539 citing authors

#	Article	IF	Citations
1	The RING Heterodimer BRCA1-BARD1 Is a Ubiquitin Ligase Inactivated by a Breast Cancer-derived Mutation. Journal of Biological Chemistry, 2001, 276, 14537-14540.	1.6	576
2	ROC1, a Homolog of APC11, Represents a Family of Cullin Partners with an Associated Ubiquitin Ligase Activity. Molecular Cell, 1999, 3, 535-541.	4.5	429
3	Targeted ubiquitination of CDT1 by the DDB1â€“CUL4Aâ€“ROC1 ligase in response to DNA damage. Nature Cell Biology, 2004, 6, 1003-1009.	4.6	322
4	Binding and recognition in the assembly of an active BRCA1/BARD1 ubiquitin-ligase complex. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 5646-5651.	3.3	314
5	Cytoplasmic destruction of p53 by the endoplasmic reticulum-resident ubiquitin ligase â€˜Synoviolinâ€™. EMBO Journal, 2007, 26, 113-122.	3.5	313
6	Stem-Loop Binding Protein, the Protein That Binds the 3â€² End of Histone mRNA, Is Cell Cycle Regulated by Both Translational and Posttranslational Mechanisms. Molecular and Cellular Biology, 2000, 20, 4188-4198.	1.1	226
7	Mass Spectrometric and Mutational Analyses Reveal Lys-6-linked Polyubiquitin Chains Catalyzed by BRCA1-BARD1 Ubiquitin Ligase. Journal of Biological Chemistry, 2004, 279, 3916-3924.	1.6	202
8	BRCA1-Associated Protein 1 Interferes with BRCA1/BARD1 RING Heterodimer Activity. Cancer Research, 2009, 69, 111-119.	0.4	175
9	A FancD2-Monoubiquitin Fusion Reveals Hidden Functions of Fanconi Anemia Core Complex in DNA Repair. Molecular Cell, 2005, 19, 841-847.	4.5	134
10	HERC2 Is an E3 Ligase That Targets BRCA1 for Degradation. Cancer Research, 2010, 70, 6384-6392.	0.4	131
11	The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1. Molecular and Cellular Biology, 2000, 20, 8185-8197.	1.1	130
12	Nucleophosmin/B23 Is a Candidate Substrate for the BRCA1-BARD1 Ubiquitin Ligase. Journal of Biological Chemistry, 2004, 279, 30919-30922.	1.6	128
13	Ubiquitin and breast cancer. Oncogene, 2004, 23, 2079-2088.	2.6	118
14	Ubiquitin acetylation inhibits polyubiquitin chain elongation. EMBO Reports, 2015, 16, 192-201.	2.0	116
15	The ubiquitin E3 ligase activity of BRCA1 and its biological functions. Cell Division, 2008, 3, 1.	1.1	100
16	Elevated expression of protein regulator of cytokinesis 1, involved in the growth of breast cancer cells. Cancer Science, 2007, 98, 174-181.	1.7	97
17	Involvement of kinesin family member 2C/mitotic centromereâ€associated kinesin overexpression in mammary carcinogenesis. Cancer Science, 2008, 99, 62-70.	1.7	94
18	Recruitment of Phosphorylated NPM1 to Sites of DNA Damage through RNF8-Dependent Ubiquitin Conjugates. Cancer Research, 2010, 70, 6746-6756.	0.4	92

#	Article	IF	Citations
19	Essential Role of Synoviolin in Embryogenesis. Journal of Biological Chemistry, 2005, 280, 7909-7916.	1.6	91
20	Expression of Î²-catenin in normal breast tissue and breast carcinoma: a comparative study with epithelial cadherin and Î±-catenin. Histopathology, 1996, 29, 139-146.	1.6	83
21	Interaction of BARD1 and HP1 Is Required for BRCA1 Retention at Sites of DNA Damage. Cancer Research, 2015, 75, 1311-1321.	0.4	83
22	Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. Breast Cancer Research, 2010, 12, R17.	2.2	79
23	Activation of UBC5 Ubiquitin-conjugating Enzyme by the RING Finger of ROC1 and Assembly of Active Ubiquitin Ligases by All Cullins. Journal of Biological Chemistry, 2002, 277, 15758-15765.	1.6	70
24	Clinicopathological analyses of triple negative breast cancer using surveillance data from the Registration Committee of the Japanese Breast Cancer Society. Breast Cancer, 2010, 17, 118-124.	1.3	67
25	LSD1 Overexpression Is Associated with Poor Prognosis in Basal-Like Breast Cancer, and Sensitivity to PARP Inhibition. PLoS ONE, 2015, 10, e0118002.	1.1	67
26	A DNA-Damage Selective Role for BRCA1 E3 Ligase in Claspin Ubiquitylation, CHK1 Activation, and DNA Repair. Current Biology, 2012, 22, 1659-1666.	1.8	57
27	Association with cullin partners protects ROC proteins from proteasome-dependent degradation. Oncogene, 1999, 18, 6758-6766.	2.6	48
28	MED12 exon 2 mutations in phyllodes tumors of the breast. Cancer Medicine, 2015, 4, 1117-1121.	1.3	46
29	BRCA1 Ubiquitinates RPB8 in Response to DNA Damage. Cancer Research, 2007, 67, 951-958.	0.4	44
30	HERC2 Interacts with Claspin and Regulates DNA Origin Firing and Replication Fork Progression. Cancer Research, 2011, 71, 5621-5625.	0.4	44
31	The BRCA1 ubiquitin ligase and homologous recombination repair. FEBS Letters, 2011, 585, 2836-2844.	1.3	43
32	Inhibition of caspase-9 activity and Apaf-1 expression in cisplatin-resistant head and neck squamous cell carcinoma cells. Auris Nasus Larynx, 2003, 30, 85-88.	0.5	42
33	HERC2 Facilitates BLM and WRN Helicase Complex Interaction with RPA to Suppress G-Quadruplex DNA. Cancer Research, 2018, 78, 6371-6385.	0.4	41
34	Fbxo22-mediated KDM4B degradation determines selective estrogen receptor modulator activity in breast cancer. Journal of Clinical Investigation, 2018, 128, 5603-5619.	3.9	39
35	Down-regulation of BRCA1-BARD1 ubiquitin ligase by CDK2. Cancer Research, 2005, 65, 6-10.	0.4	39
36	NF-ÎºB signaling mediates acquired resistance after PARP inhibition. Oncotarget, 2015, 6, 3825-3839.	0.8	35

#	Article	IF	Citations
37	Class I histone deacetylase inhibitors inhibit the retention of <scp>BRCA</scp>1 and 53<scp>BP</scp>1 at the site of <scp>DNA</scp> damage. Cancer Science, 2015, 106, 1050-1056.	1.7	28
38	A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats. Cancer Letters, 2006, 233, 108-116.	3.2	27
39	Hoxb4 transduction down-regulates Geminin protein, providing hematopoietic stem and progenitor cells with proliferation potential. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 21529-21534.	3.3	26
40	In vitro ubiquitination of cyclin D1 by ROC1-CUL1 and ROC1-CUL3. FEBS Letters, 2001, 494, 181-185.	1.3	25
41	Aberrant <scp>DNA</scp> methylation status of <scp>DNA</scp> repair genes in breast cancer treated with neoadjuvant chemotherapy. Genes To Cells, 2013, 18, 1120-1130.	0.5	24
42	Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response. Current Cancer Drug Targets, 2016, 16, 101-109.	0.8	23
43	Putative tumor suppressor EDD interacts with and upâ€regulates APC. Genes To Cells, 2007, 12, 1339-1345.	0.5	20
44	The UPS: a promising target for breast cancer treatment. BMC Biochemistry, 2008, 9, S2.	4.4	20
45	Perturbation of DNA repair pathways by proteasome inhibitors corresponds to enhanced chemosensitivity of cells to DNA damage-inducing agents. Cancer Chemotherapy and Pharmacology, 2009, 64, 1039-1046.	1.1	20
46	HERC2 regulates RPA2 by mediating ATR-induced Ser33 phosphorylation and ubiquitin-dependent degradation. Scientific Reports, 2019, 9, 14257.	1.6	15
47	TP53/p53-FBXO22-TFEB controls basal autophagy to govern hormesis. Autophagy, 2021, 17, 3776-3793.	4.3	15
48	Alterations in CD45 Glycosylation Pattern Accompanying Different Cell Proliferation States. Biochemical and Biophysical Research Communications, 1994, 200, 1283-1289.	1.0	14
49	Prospective Evaluation of Skin Surface Electropotentials in Japanese Patients with Suspicious Breast Lesions. Japanese Journal of Cancer Research, 1996, 87, 1092-1096.	1.7	14
50	HP1 regulates the localization of FANCJ at sites of DNA doubleâ€strand breaks. Cancer Science, 2016, 107, 1406-1415.	1.7	14
51	A mitotic role for the DNA damage-responsive CHK2 kinase. Nature Cell Biology, 2010, 12, 424-425.	4.6	12
52	Liganded ERÎ± Stimulates the E3 Ubiquitin Ligase Activity of UBE3C to Facilitate Cell Proliferation. Molecular Endocrinology, 2015, 29, 1646-1657.	3.7	11
53	FBXO22, an epigenetic multiplayer coordinating senescence, hormone signaling, and metastasis. Cancer Science, 2020, 111, 2718-2725.	1.7	10
54	The CUL1 C-Terminal Sequence and ROC1 Are Required for Efficient Nuclear Accumulation, NEDD8 Modification, and Ubiquitin Ligase Activity of CUL1. Molecular and Cellular Biology, 2000, 20, 8185-8197.	1.1	10

#	Article	IF	Citations
55	Targeted substrate degradation by an engineered double RING ubiquitin ligase. Biochemical and Biophysical Research Communications, 2002, 295, 370-375.	1.0	9
56	Contemplating chemosensitivity of basal-like breast cancer based on BRCA1 dysfunction. Breast Cancer, 2009, 16, 268-274.	1.3	9
57	Clinical efficacy and value of redistributed subclavian arterial infusion chemotherapy for locally advanced breast cancer. Japanese Journal of Radiology, 2011, 29, 236-243.	1.0	9
58	Analysis of Cdc2 and Cyclin D1 expression in breast cancer by immunoblotting. Breast Cancer, 1997, 4, 17-24.	1.3	8
59	HERC2 inactivation abrogates nucleolar localization of RecQ helicases BLM and WRN. Scientific Reports, 2021, 11, 360.	1.6	8
60	Radiologic-pathological correlation of punctate hyperechoic foci by ultrasound in stereotactic vacuum-assisted breast biopsy samples. Japanese Journal of Radiology, 2009, 27, 438-443.	1.0	6
61	RNF168 E3 ligase participates in ubiquitin signaling and recruitment of SLX4 during DNA crosslink repair. Cell Reports, 2021, 37, 109879.	2.9	6
62	Behavior of the Cell Cycle-Associated Proteins in an Unusual G0-Arrestable Cancer Cell Line. Experimental Cell Research, 1996, 225, 85-92.	1.2	5
63	The BARD1/HP1 interaction: Another clue to heterochromatin involvement in homologous recombination. Molecular and Cellular Oncology, 2016, 3, e1030535.	0.3	5
64	Sensitization of head and neck squamous cell carcinoma cells to Fas-mediated apoptosis by the inhibition of Bcl-XL expression. Auris Nasus Larynx, 2003, 30, 79-84.	0.5	4
65	Chromatin Regulation by HP1Î³ Contributes to Survival of 5-Azacytidine-Resistant Cells. Frontiers in Pharmacology, 2018, 9, 1166.	1.6	4
66	Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer. Cancer, 1992, 70, 741-748.	2.0	3
67	The ZZ domain of HERC2 is a receptor of arginylated substrates. Scientific Reports, 2022, 12, 6063.	1.6	2
68	MALIGNANT SCHWANNOMA OF THE STOMACH -REPORT OF A CASE-. The Journal of the Japanese Practical Surgeon Society, 1996, 57, 588-592.	0.0	1
69	Clinical Study on Anti-tumor Activities of Peripheral Blood Lymphocytes and Regional Lymph Node Lymphocytes in Gastric Cancer.. Japanese Journal of Gastroenterological Surgery, 1991, 24, 1932-1937.	0.0	0